secwatch.observer — SEC 8-K summary
======================================

Issuer:     Contineum Therapeutics, Inc. (CTNM)
CIK:        0001855175
Form:       8-K
Filed at:   2025-05-14T23:59:59+00:00
Accession:  0001437749-25-016877
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Contineum Q1 net loss $16.0M, cash $190.7M; files $300M shelf & $75M ATM
------------------------------------------------------------------------

- Net loss of $16.0M vs $8.4M in Q1 2024; R&D expenses rose 76% to $13.7M.
- Cash and equivalents of $190.7M; runway projected through 2027.
- Files $300M universal shelf registration and $75M at-the-market (ATM) equity facility with Leerink Partners.
- PIPE-791 Phase 1b PET topline data expected Q2 2025; Phase 2 initiation in IPF and PrMS planned H2 2025.
- PIPE-307 Phase 2 VISTA RRMS topline data anticipated H2 2025; J&J Phase 2 MDD trial recruiting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1855175/000143774925016877/0001437749-25-016877-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1855175/000143774925016877/cont20250321_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-016877

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer